T. Rowe Price Investment Management
TXG icon

T. Rowe Price Investment Management’s 10x Genomics TXG Stock Holding History

T. Rowe Price Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.6M Sell
1,266,954
-12,428
-1% -$326K 0.03% 405
2026
Q1 		$27.2M Sell
1,279,382
-121
-0% -$2.42K 0.02% 431
2025
Q4 		$20.9M Sell
1,279,503
-62,920
-5% -$950K 0.01% 486
2025
Q3 		$15.7M Buy
1,342,423
+364,738
+37% +$4.76M 0.01% 533
2025
Q2 		$11.3M Buy
+977,685
New +$8.91M 0.01% 549
2024
Q4 		– Sell
-2,161,775
Closed -$48.8M – 674
2024
Q3 		$48.8M Sell
2,161,775
-1,204
-0.1% -$24.9K 0.03% 409
2024
Q2 		$42.1M Sell
2,162,979
-41,451
-2% -$1.09M 0.03% 411
2024
Q1 		$82.7M Buy
2,204,430
+1,063,386
+93% +$46.7M 0.05% 316
2023
Q4 		$63.9M Buy
1,141,044
+144,379
+14% +$6.28M 0.04% 353
2023
Q3 		$41.1M Hold
996,665
– – 0.03% 392
2023
Q2 		$55.7M Sell
996,665
-29,296
-3% -$1.59M 0.04% 363
2023
Q1 		$57.2M Buy
+1,025,961
New +$47.9M 0.04% 347

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Investment Management's TXG Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its 10x Genomics (TXG) stake by 0.97% in Q2 2026, selling an estimated $326K and leaving 1,266,954 shares worth $48.6M. The position accounts for 0.03% of the portfolio, ranked #405.

T. Rowe Price Investment Management first reported a position in TXG in Q1 2023 and has held it in 12 quarters since. The position peaked at $82.7M in Q1 2024. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • T. Rowe Price Investment Management held 1,266,954 shares of 10x Genomics worth $48.6M as of Q2 2026.
  • T. Rowe Price Investment Management sold 12,428 10x Genomics shares in Q2 2026, an estimated $326K.
  • 10x Genomics made up 0.03% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #405 holding.
  • T. Rowe Price Investment Management first reported a position in 10x Genomics in Q1 2023 and has held it in 12 quarters since.
  • T. Rowe Price Investment Management's 10x Genomics position peaked at $82.7M in Q1 2024.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.